– NETHERLANDS, Utrecht – InteRNA Technologies today announced the closing of an extended Series B financing totaling EUR 18.5M, led by AurorA Science, an Italian biotech investment company, along with existing investor Waterman Ventures. Current shareholders Aglaia Oncology Funds and OostNL also contributed to the financing round.
Concurrent with the financing, Dr. Gabriele Campi, Ph.D. of AurorA Science will join the Board of Directors.
The funding will enable the clinical evaluation of the microRNA lead candidate, INT-1B3, in patients with advanced solid tumors. Furthermore, the proceeds will be used to develop and advance additional proprietary preclinical drug candidates addressing a variety of cancer indications thereby expanding the Company’s pipeline.
“This successful extension of the Series B financing round validates the unique potential that microRNAs offer as a therapeutic modality for hard-to-treat cancers,” said CEO, Dr. Roel Schaapveld. “We thank AurorA Science, Waterman Ventures, and our other long-term investors for their support in bringing our microRNA technology into the clinic and look forward to evaluate INT-1B3’s unique mode of action, targeting not only the tumor cells themselves but also the disease-promoting tumor microenvironment.”
“With this participation in InteRNA Technologies, AurorA Science continues its strong commitment to front-edge science,” commented Guido Guidi, Chairman at AurorA Science. “We believe InteRNA has developed a promising innovative technology in this area and look forward to supporting the team on their path forward.”
About InteRNA Technologies
InteRNA is a Dutch clinical-stage biotech company developing a pipeline of proprietary microRNA therapeutics targeting key processes in the initiation and progression of human diseases, with a focus on cancer. Selected through InteRNA’s leading miRNA discovery and functional validation platform and enabled with a 3rd generation drug delivery formulation, these miRNA compounds can mount a coordinated anti-cancer attack by engaging multiple signal transduction targets simultaneously. With this approach, we address the high need for novel therapeutics with improved efficacy and less prone to drug-acquired resistance that will benefit cancer patients.
For more information: https://interna-technologies.com/
About AurorA Science
AurorA Science is a biotech investment company integrating an innovative financial and industrial approach in the research and development challenges. The company is focused on independent and entrepreneurial biotech start-ups in Europe with high therapeutic potential, providing industrial and financial support.
For more information: https://aurorascience.eu/
About Waterman Ventures
Waterman Ventures invests in ambitious technology companies that combine a positive impact on society with a healthy financial return. Over the last 30 years, we have been a long term partner to many successful businesses. Our team, based in the Netherlands, shares a passion for technology and a hands-on mindset to support growth in our portfolio companies.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
